Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 03:22PM ET
56.67
Dollar change
+0.29
Percentage change
0.52
%
CategoryUS Equities - Industry Sector Asset TypeEquities (Stocks) TagsU.S. Return% 1Y15.94% Shs Outstand Perf Week0.08%
SponsorVirtus ETF Solutions ETF Type Tagsequity Return% 3Y2.84% Total Holdings104 Perf Month-7.87%
Fund Family Bond Type Tagshealthcare Return% 5Y4.96% AUM19.84M Perf Quarter-3.61%
IndexLifeSci Biotechnology Products Index Average Maturity Tagsbiotechnology Return% 10Y NAV% Perf Half Y11.08%
Index Weighting Commodity Type Tags- Return% SI NAV/sh Perf Year16.79%
Active/Passive Quant Type Tags- Flows% 1M0.00% 52W Range45.00 - 63.25 Perf YTD-2.45%
Dividend TTM- ESG Type Tags- Flows% 3M18.17% 52W High-10.40% Beta0.62
Dividend Ex-DateDec 20, 2017 Dividend Type Sector/Theme Flows% YTD18.17% 52W Low25.93% ATR (14)0.88
Expense0.79% Structure Type Region Flows% 1Y RSI (14)46.08 Volatility0.96% 1.38%
Option/ShortYes / No Growth/Value Dev/Emerg Flows% 3Y Rel Volume0.61 Prev Close56.38
Inverse/Leveraged Market Cap Currency Flows% 5Y Avg Volume3.68K Price56.67
SMA20-1.01% SMA50-2.71% SMA2005.38% Trades Volume2,170 Change0.52%
Virtus LifeSci Biotech Products ETF seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with at least one drug therapy approved by the U.S. Food and Drug Administration ("FDA") for marketing.